

Neuland Laboratories Limited

11th Floor (5th Office Level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad - 500033, Telangana, India.

Tel: 040 67611600 / 67611700 Email: neuland@neulandlabs.com www.neulandlabs.com

October 28, 2022

To **BSE Limited** Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001

The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai - 400 001

Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Results Release and Earnings Call Notice - Revised intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the schedule of Q2 FY 2023 Earnings Call details. Please note that there is no change from the earlier intimation, except that the URL is provided below.

For Diamond pass registration please click on the below URL:

 $\frac{https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7225038\&1inkSecurityString=219e06b0e0$

This is for your information and records.

Thanking you,

Yours faithfully, For **Neuland Laboratories Limited**

Sarada Bhamidipati Company Secretary

Encl: As above



Neuland Laboratories Limited's Q2FY23 Results Conference Call

Neuland Laboratories Limited will announce its results for the second quarter and half year ended September 30, 2022 on November 10, 2022. The results will also be made available on the website of the Company, www.neulandlabs.com

Following the announcement, the management of the Company will host an Earnings Call on November 10, 2022 at 17:00 hrs.

The details of the earnings call are:

Date: November 10, 2022

Time: **17:00 Hrs (IST)**

For Diamond Pass Registration Please Click Here:

Diamond Pass

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANDLAB)

For over 38 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 900 Regulatory filings in the US (62 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For more information, visit www.NeulandLabs.com

For more queries please contact:

Neuland: ir@neulandlabs.com

Ravi Udeshi: ravi.udeshi@in.ey.com